LPTI Longport Inc (CE)

Longport, Inc. (OTC BB: LPTI): -- Clinical Symposium in Skin & Wound Care - Las Vegas - October 23-26 -- Wound, Ostomy And Continence Nurses Society - Galveston - October 22-27 -- Texas Health Care Association - Dallas - November 7-9 Longport, Inc., (OTC BB: LPTI), a medical technology specialist in high resolution ultrasound imaging, announced today that its EPISCAN I-200 will be showcased at three separate conferences in the coming weeks. Longport will attend and display the EPISCAN I-200 at the annual Clinical Symposium in Skin & Wound Care in Las Vegas, NV, October 23-26. At this year's conference, organizers expect 1,300 multidisciplinary practitioners - nurses, physicians, podiatrists, physical therapists, and other professionals who manage skin and wound care patients across the continuum of health care. In addition, Maximum Medical, which has purchased six EPISCAN I-200 demonstration systems, will showcase the technology at both a South Central Regional conference of the Wound, Ostomy, and Continence Nurses Society on October 22-27 in Galveston, TX, and the Texas Health Care Association meeting on November 7-9 in Dallas, TX. Paul Wilson, President of Longport, said, "We are very pleased to be able to show the EPISCAN I-200 at these conferences, where the practitioners of wound care can see for themselves how easy it is to use the scanner, as well as for us to be able to discuss the impact of the scanner on wound assessment and prevention with a range of clinicians. Longport is particularly pleased that Maximum Medical is taking the EPISCAN I-200 to the shows they are attending to reinforce our sales message. We look forward to attending additional wound conferences as well as events focused on dermatology and aesthetics in the near future." About Longport, Inc. Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights, and FDA permission to market. The Company's technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com. Forward-looking Information and the Private Securities Litigation Reform Act of 1995 Certain statements in this press release, including statements concerning product development milestones and anticipated events, are "forward-looking statements" within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport's actual results include, among others, uncertainties as to the Company's ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport's 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.